Eli Lilly (Mexico) Performance
| LLY Stock | MXN 16,180 68.23 0.42% |
The firm shows a Beta (market volatility) of 0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eli Lilly's returns are expected to increase less than the market. However, during the bear market, the loss of holding Eli Lilly is expected to be smaller as well. At this point, Eli Lilly has a negative expected return of -0.19%. Please make sure to confirm Eli Lilly's treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Eli Lilly performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Eli Lilly and has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
| Begin Period Cash Flow | 3.8 B |
Eli |
Eli Lilly Relative Risk vs. Return Landscape
If you would invest 1,857,204 in Eli Lilly and on September 2, 2024 and sell it today you would lose (239,154) from holding Eli Lilly and or give up 12.88% of portfolio value over 90 days. Eli Lilly and is producing return of less than zero assuming 2.4049% volatility of returns over the 90 days investment horizon. Simply put, 21% of all stocks have less volatile historical return distribution than Eli Lilly, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Eli Lilly Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eli Lilly's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eli Lilly and, and traders can use it to determine the average amount a Eli Lilly's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0791
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LLY |
Estimated Market Risk
| 2.4 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eli Lilly is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eli Lilly by adding Eli Lilly to a well-diversified portfolio.
Eli Lilly Fundamentals Growth
Eli Stock prices reflect investors' perceptions of the future prospects and financial health of Eli Lilly, and Eli Lilly fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eli Stock performance.
| Return On Equity | 0.65 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 6.99 T | |||
| Shares Outstanding | 950.18 M | |||
| Price To Earning | 333.06 X | |||
| Price To Book | 34.76 X | |||
| Price To Sales | 231.96 X | |||
| Revenue | 28.54 B | |||
| EBITDA | 8.28 B | |||
| Cash And Equivalents | 2.2 B | |||
| Cash Per Share | 2.39 X | |||
| Total Debt | 15.35 B | |||
| Debt To Equity | 648.20 % | |||
| Book Value Per Share | 11.19 X | |||
| Cash Flow From Operations | 7.26 B | |||
| Earnings Per Share | 123.49 X | |||
| Total Asset | 48.81 B | |||
About Eli Lilly Performance
Evaluating Eli Lilly's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Eli Lilly has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Eli Lilly has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. ELI LILLY operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 33610 people.Things to note about Eli Lilly performance evaluation
Checking the ongoing alerts about Eli Lilly for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eli Lilly help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eli Lilly generated a negative expected return over the last 90 days | |
| Eli Lilly has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Over 85.0% of the company shares are owned by institutional investors |
- Analyzing Eli Lilly's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eli Lilly's stock is overvalued or undervalued compared to its peers.
- Examining Eli Lilly's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eli Lilly's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eli Lilly's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eli Lilly's stock. These opinions can provide insight into Eli Lilly's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.